(ORMP) Oramed Pharmaceuticals Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ORMP) Oramed Pharmaceuticals Inc. Complete Analysis Pack
Oramed Pharmaceuticals: Business Model Canvas
Unlock the full strategic blueprint behind Oramed Pharmaceuticals Inc.’s business model. This Business Model Canvas breaks down how the company creates value, builds partnerships, and positions itself in the competitive biotech space. Ideal for investors, analysts, and entrepreneurs seeking practical, company-specific insights.
Partnerships
CROs for Phase II and Phase I trials
CROs run Oramed Pharmaceuticals Inc.'s Phase I and Phase II work for ORMD-0801 and ORMD-0901, covering patient enrollment, site monitoring, and data capture. For a clinical-stage company with 2 lead assets, this outsourced model helps keep trials moving while protecting cash and scaling across multiple study sites.
Clinical trial sites in diabetes care
Clinical trial sites in diabetes care give Oramed Pharmaceuticals Inc. access to the 537 million adults living with diabetes worldwide, including about 90% with type 2 diabetes. That patient pool helps generate the safety and efficacy data needed for oral peptide delivery and can shorten enrollment timelines.
CMOs for GMP capsule manufacturing
Oramed Pharmaceuticals relies on CMOs with GMP lines to make oral insulin and GLP-1 capsules at scale, with batch release testing and tighter lot-to-lot consistency. This lets the Company avoid heavy factory capex and keeps fixed assets lighter while it pushes outsourced manufacturing through clinical and commercial stages.
Regulatory and ethics bodies
FDA and institutional review boards are critical partners for Oramed Pharmaceuticals Inc. because they approve study design, monitor human-subject ethics, and shape trial protocols, labeling claims, and milestone timing. For a drug developer, regulatory alignment is not optional; it directly affects whether a program can move from Phase 1 to approval.
- FDA sets trial and labeling rules
- IRBs protect patient safety
- Approval timing drives milestones
Future pharma license and commercialization partners
Oramed Pharmaceuticals Inc.’s oral peptide platform is built for licensing, so future pharma partners can extend reach, fund late-stage trials, and help with market access. That matters because the portfolio is still pre-commercial, so partner capital can reduce Oramed Pharmaceuticals Inc.’s funding load before launch.
- Partners fund late-stage development
- Partners widen global market access
- Best fit for pre-commercial assets
Oramed’s Outsourced Network Powers Diabetes Trial Execution
Oramed Pharmaceuticals Inc. depends on CROs, CMOs, and diabetes trial sites to run ORMD-0801 and ORMD-0901 without building a full in-house network. With 537 million adults living with diabetes worldwide and about 90% having type 2 diabetes, these partners keep enrollment, GMP supply, and execution moving.
| Partner | Role | Key data |
|---|---|---|
| CROs | Run trials | Phase I-II |
| CMOs | Make capsules | Lower capex |
| Sites | Enroll patients | 537M cases |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Oramed Pharmaceuticals Inc. that maps its drug development, partnerships, and commercialization strategy.
Customizable Excel Spreadsheet
Quickly maps Oramed’s business model to spot pain points and support smarter decisions.
Reference Sources
Gives Oramed Pharmaceuticals Inc. a credible source trail that supports faster, more confident investment and strategy decisions.
Activities
Oral peptide formulation R&D
Oramed Pharmaceuticals Inc.'s key activity is oral peptide formulation R&D, building capsule-based delivery for proteins and peptides. The platform targets 3 core molecules, insulin, GLP-1, and leptin, and sits at the technical center of the business.
Clinical development of ORMD-0801
ORMD-0801 has already completed Phase II diabetes trials, so Oramed Pharmaceuticals Inc. must keep generating data, analyzing results, and planning publications to support the asset’s next step. In a company that remains clinical-stage, advancing one lead program from Phase II is a core value driver, because each new dataset can materially shape partner interest, valuation, and funding options.
Clinical development of ORMD-0901
ORMD-0901 has completed 1 Phase I study in type 2 diabetes, and the next steps are dose refinement plus later-phase trials. That keeps Oramed Pharmaceuticals Inc. in the oral GLP-1 race, a space built around replacing injections with a pill.
CMC and manufacturing process development
Oramed Pharmaceuticals Inc. must keep refining formulation, stability, and release testing so each capsule is reproducible and meets CMC standards before scale-up. This work is the gate before larger commercialization, and it ties directly to GMP-ready batch consistency.
- Refine capsule formulation
- Prove stability over time
- Lock in release methods
- Support repeatable production
- Enable scale-up readiness
Regulatory strategy and IP management
Oramed must keep patent filings, scientific disclosures, and FDA submissions tightly aligned, because its oral delivery platform only stays defensible if claims are filed early and protected for up to 20 years from the filing date. Strong regulatory planning also cuts trial and filing risk across programs, which matters for a biotech with limited room for delays.
- Protect oral delivery IP early
- Coordinate disclosures with filings
- Plan FDA steps to lower risk
Oramed’s Oral Peptide Pipeline Advances Toward Later-Stage Proof
Oramed Pharmaceuticals Inc. keeps its value tied to oral peptide R&D, with ORMD-0801 already through Phase II and ORMD-0901 through 1 Phase I study. It must keep running clinical data, CMC testing, and IP filings to move capsule delivery toward later-stage proof and protect the platform.
| Activity | Data |
|---|---|
| Clinical | 2 active programs |
| ORMD-0801 | Phase II done |
| ORMD-0901 | 1 Phase I study |
What You See Is What You Get
Business Model Canvas
This Oramed Pharmaceuticals Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It is not a sample or mockup—what you see here is a live view of the same file, with the same content and formatting. Once your order is complete, you’ll get full access to this identical, ready-to-use document.
Resources
Oral delivery technology platform
Oramed Pharmaceuticals Inc.’s oral delivery technology platform is its core know-how asset, built to deliver polypeptides by mouth instead of injection. One platform supports multiple product candidates, giving the company a single technical base for several pipeline programs.
Lead assets ORMD-0801 and ORMD-0901
ORMD-0801 and ORMD-0901 are Oramed Pharmaceuticals Inc.’s two most advanced assets, both backed by Phase 2 diabetes data. With 2 lead programs and clinical proof points in a large chronic market, they carry clear partnering and licensing value as oral delivery can support wider scale-up and deal interest.
Clinical data from Phase II and Phase I trials
Oramed Pharmaceuticals Inc. uses Phase I and Phase II clinical data as a core intangible asset, especially the 180-patient Phase 2b oral insulin trial, to show scientific credibility to regulators and investors. These results also guide go/no-go calls, dose selection, and the next study design.
Patent portfolio and proprietary know-how
Oramed Pharmaceuticals Inc. relies on its patent portfolio and capsule know-how to protect oral drug delivery, including formulation, delivery, and composition claims. In pharma, patent terms typically run 20 years from filing, so this IP is central to blocking copycats and keeping Oramed’s oral capsule platform defensible.
- Protects formulation and delivery claims
- Capsule design know-how is strategic
- Patent life supports market exclusivity
Scientific and regulatory team
Oramed Pharmaceuticals Inc. relies on a scientific and regulatory team to run research, review data, and prepare FDA filings. For a small biotech, this human capital matters because one filing cycle can shape cash use, trial timing, and approval odds.
- Drives R&D and data analysis
- Prepares regulatory submissions
- Supports compliance and filings
Oramed’s Oral Platform Is Backed by 180-Patient Phase 2b Data
Key resources at Oramed Pharmaceuticals Inc. are its oral delivery platform, patent estate, and clinical data set. The company’s 2 lead programs, ORMD-0801 and ORMD-0901, are anchored by a 180-patient Phase 2b trial, which gives the platform proof in a large diabetes market.
| Resource | Data |
|---|---|
| Lead programs | 2 |
| Phase 2b trial | 180 patients |
Value Propositions
Needle-free oral insulin delivery
ORMD-0801 turns insulin into a capsule, aiming to replace or support injections and make daily diabetes care easier. With about 589 million adults living with diabetes worldwide in 2024, a needle-free option could cut injection burden and improve adherence for a very large patient base.
Oral GLP-1 option for type 2 diabetes
ORMD-0901 extends Oramed Pharmaceuticals Inc.'s oral delivery platform beyond insulin into the GLP-1 class, where injectables still dominate care. Oral dosing can lift adherence and adoption; Novo Nordisk's oral semaglutide, Rybelsus, already proves pill-based GLP-1 demand in type 2 diabetes.
Oral leptin program for weight loss
Oramed Pharmaceuticals Inc.’s oral leptin capsule extends its delivery platform into obesity care, adding a second metabolic market beyond diabetes and broadening pipeline risk/reward. That matters in a market where obesity affects over 1 billion people worldwide in 2025, so a successful oral option could open a much larger commercial pool than diabetes alone.
Potential adherence and convenience benefits
Oramed Pharmaceuticals Inc.'s oral capsule value proposition is simple: pills are easier to take than injections, so they can improve daily adherence in chronic disease care. For patients, that convenience can support routine use and lower treatment friction; that matters because even small dose burdens can cut persistence in long-term therapies.
- Oral use is easier than injections
- Convenience supports routine adherence
- Lower friction improves patient uptake
Platform approach across multiple polypeptides
Oramed Pharmaceuticals Inc.’s oral delivery platform can support multiple polypeptides, so one science stack and one manufacturing base can serve several programs. That cuts reinvention across assets and can speed pipeline expansion; as of FY2025, this kind of platform reuse matters even more for capital efficiency in a thin-margin biotech model.
- One delivery system, many drug candidates
- Shared science lowers program duplication
- Shared manufacturing can cut scale-up work
Oramed’s Oral-First Play on Diabetes and Obesity
Oramed Pharmaceuticals Inc. sells a simple idea: turn chronic injectable therapies into oral capsules, which can reduce treatment friction and support adherence in diabetes, obesity, and other peptide-led diseases. That fits a huge base, with about 589 million adults living with diabetes in 2024 and over 1 billion people affected by obesity in 2025.
| Value driver | Why it matters |
|---|---|
| Oral dosing | Easier than injections |
| Platform reuse | One stack across programs |
| Market size | Diabetes 589M; obesity 1B+ |
Customer Relationships
Physician-led prescription relationships
Patients with diabetes usually start treatment through physicians, so Oramed must win trust from endocrinologists and diabetes specialists. With about 589 million adults living with diabetes worldwide, clinical evidence matters: prescribing hinges on proof of safety, efficacy, and real-world outcomes, not brand talk.
Evidence-driven engagement
Oramed Pharmaceuticals Inc. must win on published trial data, not brand. In FY2025, it still had no product sales, so medical buyers will judge safety and efficacy results first, with peer-reviewed publications doing more than consumer-style marketing.
Trial participant support
Oramed Pharmaceuticals Inc. depends on site teams and coordinators to secure informed consent, keep follow-up visits on schedule, and maintain protocol compliance across clinical studies. A strong trial experience lifts retention and data quality, which matters in studies where missed visits or dropouts can weaken endpoints and delay readouts.
Partner account management
Partner account management is central for Oramed Pharmaceuticals Inc. when it licenses assets, because each pharma partner needs tight tracking of milestones, reports, and joint development work. In 2024, Oramed still relied on partner-driven value creation around its licensed programs, so these long-cycle relationships must be managed like high-value accounts, not one-off deals.
- Track milestones closely
- Share reporting on schedule
- Coordinate joint development plans
- Protect long-cycle partner value
Investor and stakeholder communications
Oramed Pharmaceuticals Inc. must keep investors updated on trial readouts, patent progress, and funding moves, because each disclosure can shift market confidence and the cost of capital. For a public biotech, this relationship is a core funding tool, not just a reporting duty.
- Trial updates move sentiment fast
- IP news supports valuation support
- Financing clarity helps capital access
Trust-Driven Growth at Oramed: No Sales, All About Data
Oramed Pharmaceuticals Inc. builds customer ties mainly through physicians, clinical sites, partners, and investors. In FY2025, it reported no product sales, so trust depends on trial data, site execution, and milestone reporting, not retail marketing.
| Customer | Key need | FY2025 fact |
|---|---|---|
| Physicians | Proof of safety | No product sales |
| Partners | Milestone tracking | Value is license-led |
| Investors | Clear updates | Funding depends on readouts |
Channels
Clinical trial sites
Clinical trial sites are Oramed Pharmaceuticals Inc.’s main execution channel for development-stage products, linking the Company to eligible patients and investigators. In 2025, site performance still drove program speed through enrollment, retention, and protocol adherence, so each delay or drop in screening can push back readouts and raise R&D spend.
Endocrinology and diabetes clinics
Endocrinology and diabetes clinics are Oramed Pharmaceuticals Inc.’s main future prescription gate, because specialists diagnose and manage the 589 million adults living with diabetes worldwide. These clinics will be key early adoption points for oral insulin and GLP-1 products, where treatment changes are made and long-term adherence is tracked.
Pharma licensing partners
Oramed Pharmaceuticals Inc. uses pharma licensing partners to reach markets its small team cannot cover alone. Partners can take on late-stage trials, registration, and commercialization, which matters because global Phase 3 programs can run into tens of millions of dollars and need local market access.
Scientific conferences and medical publications
Oramed Pharmaceuticals Inc. uses scientific conferences and medical journals to share clinical data, build trust with physicians, and educate researchers; in biotech, peer-reviewed evidence and conference talks are a core market-education channel. This matters because adoption often starts with key opinion leaders, not ads.
- Spreads trial results fast
- Builds physician credibility
- Supports researcher adoption
Corporate website and investor filings
Oramed Pharmaceuticals Inc. uses its corporate website and SEC filings as the main public disclosure channel, sharing milestones, trial updates, risk factors, and financial results. For a listed biotech, this standard channel helps build investor awareness and analyst coverage while keeping the market updated on clinical and regulatory progress.
- Shares milestones and risk factors
- Supports investor and analyst reach
- Standard for listed biotech firms
Oramed’s 2025 channels: sites, partners, and congresses drive biotech traction
Oramed Pharmaceuticals Inc.’s channels are still built around trial sites, licensing partners, and medical congresses, with the Company using each to move data from patients to regulators and then to physicians. In 2025, that mattered more because Oramed Pharmaceuticals Inc. was still a small biotech, so every enrollment win, partner step, and publication had to carry more commercial weight.
| Channel | 2025 use |
|---|---|
| Trial sites | Patient enrollment |
| Licensing partners | Late-stage reach |
| Journals/congresses | Physician trust |
Customer Segments
Patients with diabetes
Patients with diabetes are Oramed Pharmaceuticals Inc.’s core end users, especially the millions needing daily glucose control over years. The International Diabetes Federation estimated 589 million adults aged 20-79 were living with diabetes in 2024, and oral delivery matters because it may reduce injection burden and improve adherence.
Type 2 diabetes patients
Type 2 diabetes patients are ORMD-0901’s core target, and they sit in one of the largest chronic disease markets: about 589 million adults worldwide live with diabetes, and roughly 90% have type 2. This segment is key for oral GLP-1 adoption because many patients still prefer pills over injections.
People seeking weight-loss therapies
Oramed Pharmaceuticals Inc.'s oral leptin program targets people seeking weight-loss therapies, putting it in the obesity-treatment market. The customer pool is large: the WHO says over 1 billion people lived with obesity in 2022, and demand stays tied to long-term metabolic care, not one-time use.
Endocrinologists and diabetes specialists
Endocrinologists and diabetes specialists are a key professional segment for Oramed Pharmaceuticals Inc. because they shape therapy choice and switching decisions. In the U.S., 38.4 million people had diabetes in 2021, so these physicians need strong clinical data, safety evidence, and clear A1C outcomes before moving patients to a new oral insulin option.
- High influence on prescribing
- Need proof before switching
- Critical for adoption in diabetes care
Pharmaceutical licensees and development partners
Pharmaceutical licensees and development partners are Oramed Pharmaceuticals Inc.’s B2B buyers for its platform and assets, paying for rights, development access, or regional commercialization. This model can bring non-dilutive funding through upfront fees, milestones, and royalties, helping fund R&D without new share issuance.
- B2B licensing and co-development
- Upfront cash plus milestones
- Regional rights and commercialization
- Non-dilutive capital source
Oramed Targets Massive Diabetes and Obesity Markets
Oramed Pharmaceuticals Inc. serves two main customer groups: patients with diabetes and obesity who want oral treatment, and doctors who decide whether to prescribe it. The addressable diabetes market is huge, with 589 million adults aged 20-79 living with diabetes in 2024, while the WHO counted over 1 billion people with obesity in 2022.
| Segment | Key data |
|---|---|
| Diabetes patients | 589M adults, 2024 |
| Obesity patients | 1B+ people, 2022 |
| U.S. doctors | 38.4M people with diabetes, 2021 |
Cost Structure
Research and development expense
Oramed Pharmaceuticals Inc. keeps research and development as a core fixed and variable cost because oral peptide delivery needs repeated formulation work, lab studies, and stability tests. In fiscal 2025, this spend stayed central to advancing oral insulin and other peptide programs, where each experiment adds cash burn but can also improve dosing, absorption, and product fit.
Clinical trial spending
Clinical trial spending is a core cost driver for Oramed Pharmaceuticals Inc., with Phase I and Phase II work often absorbing most of a clinical-stage biotech budget. Site fees, CROs, monitoring, and patient services push burn higher fast, and even one mid-stage study can run into millions of dollars.
Manufacturing and CMC costs
Oramed Pharmaceuticals Inc. bears GMP-compliant capsule production, stability testing, and batch-release costs in its CMC spend, and these are fixed overheads that climb as programs move from small trials to larger studies. In 2025, the company’s higher clinical scale would require more GMP lots, more analytical release work, and longer stability runs, which pushes manufacturing cost up fast.
Regulatory, legal, and IP costs
Oramed Pharmaceuticals Inc. keeps paying for patents, filings, and compliance because its oral-drug platform needs legal cover and regulatory support through each review step. Public-company legal work also adds SEC reporting, disclosure, and governance costs, so this line stays fixed even when sales are weak.
- Patents protect the platform.
- Filings support approvals.
- SEC and legal duties add steady overhead.
General and administrative costs
Oramed Pharmaceuticals Inc. carries general and administrative costs for finance, HR, audit, legal, and SEC reporting, plus New York headquarters occupancy and support. These overhead costs are fixed enough to hit cash burn before product sales scale, so they matter early in the Business Model Canvas.
- Finance, HR, audit, reporting
- HQ rent and support costs
- Needed before sales grow
Oramed’s 2025 Cost Load: R&D and Trials Drive Heavy Cash Burn
Oramed Pharmaceuticals Inc. cost structure in fiscal 2025 is dominated by 4 items: R&D, clinical trials, CMC manufacturing, and public-company overhead. For an oral-peptide biotech, this means heavy cash burn before revenue, with each new study and GMP batch adding cost.
| Fiscal 2025 | Main cost | Effect |
|---|---|---|
| 2025 | R&D, trials, CMC, G&A | High fixed burn |
Revenue Streams
Future product sales
Future product sales would come only after regulatory approval of Oramed Pharmaceuticals Inc.'s oral therapies, with ORMD-0801 and ORMD-0901 as the main candidates. Since Oramed Pharmaceuticals Inc. still depends on clinical and FDA success, this revenue stream is binary: no approval means no commercial sales, while approval could open a recurring product market.
Upfront licensing fees
Oramed Pharmaceuticals Inc. can earn upfront licensing fees when partners pay to secure platform or asset rights, and those payments are common in biotech deals. In recent partnering deals, upfront checks often run from $1 million to $10 million, giving Oramed non-dilutive cash to fund R&D without issuing new shares.
Milestone payments
Oramed Pharmaceuticals Inc. uses milestone payments that are triggered by trial progress and regulatory approval, so cash can arrive in staged tranches across each program. That matters because it can fund later-phase R&D without tapping as much equity, which is especially important for a Company still built around development-stage assets rather than large 2025 product sales.
Royalties on net sales
Oramed Pharmaceuticals Inc. can earn royalties on net sales if a partner commercializes its asset, so it can create long-term upside without building a full sales force. In its latest filings, this stream is still deal-dependent, with royalty rates set by contract and no steady royalty base yet; that makes partner sales the key driver.
- Partner sales can trigger royalties
- Low fixed cost, higher upside
- Rates vary by deal terms
Collaborative R and D funding
Collaborative R and D funding lets Oramed Pharmaceuticals Inc. share clinical development costs with partners, which lowers cash burn and extends runway while it remains pre-commercial. For a biotech with no steady product sales, this kind of cost sharing can be the cleanest way to keep trials moving without loading the balance sheet.
- Shares trial costs with partners
- Reduces Oramed cash burden
- Fits a pre-commercial biotech model
Oramed’s Revenue Hinges on Deals, Milestones, and FDA Wins
Oramed Pharmaceuticals Inc. still has no steady product sales, so revenue is mainly tied to licensing, upfront fees, milestones, royalties, and partner-funded R and D. That makes cash flow highly event-driven, with upside only if ORMD-0801 or ORMD-0901 wins approval.
| Stream | Current status | Cash profile |
|---|---|---|
| Product sales | Pre-approval | None yet |
| Upfront fees | Deal-based | Usually $1M-$10M |
| Milestones | Trial and FDA linked | Staged inflows |
| Royalties | Partner dependent | Long-term upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.